Loading...

Achieve Life Sciences

DB:SP4N
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SP4N
DB
$27M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
  • Achieve Life Sciences has significant price volatility in the past 3 months.
SP4N Share Price and Events
7 Day Returns
14.9%
DB:SP4N
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-69%
DB:SP4N
-10.6%
DE Biotechs
-6.2%
DE Market
SP4N Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Achieve Life Sciences (SP4N) 14.9% 31.3% 204.1% -69% - -
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • SP4N underperformed the Biotechs industry which returned -10.6% over the past year.
  • SP4N underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

SP4N Value

 Is Achieve Life Sciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Achieve Life Sciences. This is due to cash flow or dividend data being unavailable. The share price is €3.375.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Achieve Life Sciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Achieve Life Sciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:SP4N PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.61
NasdaqCM:ACHV Share Price ** NasdaqCM (2019-04-23) in USD $4.05
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Achieve Life Sciences.

DB:SP4N PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:ACHV Share Price ÷ EPS (both in USD)

= 4.05 ÷ -3.61

-1.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Achieve Life Sciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Achieve Life Sciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Achieve Life Sciences's expected growth come at a high price?
Raw Data
DB:SP4N PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
60.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Achieve Life Sciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Achieve Life Sciences's assets?
Raw Data
DB:SP4N PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.35
NasdaqCM:ACHV Share Price * NasdaqCM (2019-04-23) in USD $4.05
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:SP4N PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:ACHV Share Price ÷ Book Value per Share (both in USD)

= 4.05 ÷ 2.35

1.72x

* Primary Listing of Achieve Life Sciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Achieve Life Sciences is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Achieve Life Sciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Achieve Life Sciences has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SP4N Future Performance

 How is Achieve Life Sciences expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
60.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Achieve Life Sciences expected to grow at an attractive rate?
  • Achieve Life Sciences's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Achieve Life Sciences's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Achieve Life Sciences's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:SP4N Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:SP4N Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 60.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:SP4N Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:SP4N Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 223 185 1
2022-12-31 95 74 1
2021-12-31 0 -21 2
2020-12-31 0 -33 2
2019-12-31 0 -19 2
DB:SP4N Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -11 -13
2018-09-30 -11 -13
2018-06-30 -13 -16
2018-03-31 -11 -13
2017-12-31 -9 -11
2017-09-30 -6 -7
2017-03-31 0 -1
2016-12-31 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Achieve Life Sciences's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Achieve Life Sciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:SP4N Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Achieve Life Sciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:SP4N Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 4.46 4.46 4.46 1.00
2022-12-31 1.95 1.95 1.95 1.00
2021-12-31 -0.68 -0.54 -0.81 2.00
2020-12-31 -1.43 -1.16 -1.70 2.00
2019-12-31 -1.47 -1.01 -1.92 2.00
DB:SP4N Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.61
2018-09-30 -5.99
2018-06-30 -13.66
2018-03-31 -16.97
2017-12-31 -22.07
2017-09-30 -40.01
2017-03-31
2016-12-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Achieve Life Sciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Achieve Life Sciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Achieve Life Sciences has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SP4N Past Performance

  How has Achieve Life Sciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Achieve Life Sciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Achieve Life Sciences does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Achieve Life Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Achieve Life Sciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Achieve Life Sciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Achieve Life Sciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:SP4N Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -12.69 6.95 5.87
2018-09-30 -12.79 6.95 5.94
2018-06-30 -16.02 6.74 5.22
2018-03-31 -13.40 5.08 4.24
2017-12-31 -10.58 3.53 3.10
2017-09-30 -7.33 2.43 1.03
2017-03-31 -1.20 1.40 0.28
2016-12-31 -1.23 1.43 0.29
2015-12-31 -1.24 1.67 0.16

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Achieve Life Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Achieve Life Sciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Achieve Life Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Achieve Life Sciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Achieve Life Sciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SP4N Health

 How is Achieve Life Sciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Achieve Life Sciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Achieve Life Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Achieve Life Sciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Achieve Life Sciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Achieve Life Sciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Achieve Life Sciences Company Filings, last reported 3 months ago.

DB:SP4N Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 15.80 0.00 14.60
2018-09-30 14.16 0.00 13.15
2018-06-30 16.44 0.00 15.28
2018-03-31 6.14 0.00 4.17
2017-12-31 7.88 0.00 5.28
2017-09-30 10.68 0.00 8.02
2017-03-31 0.41 0.85 0.02
2016-12-31 0.61 0.83 0.02
2015-12-31 1.84 0.68 0.07
  • Achieve Life Sciences has no debt.
  • Achieve Life Sciences currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Achieve Life Sciences has sufficient cash runway for 1.4 years based on current free cash flow.
  • Achieve Life Sciences has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 72% each year.
X
Financial health checks
We assess Achieve Life Sciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Achieve Life Sciences has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SP4N Dividends

 What is Achieve Life Sciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Achieve Life Sciences dividends.
If you bought €2,000 of Achieve Life Sciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Achieve Life Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Achieve Life Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:SP4N Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:SP4N Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Achieve Life Sciences has not reported any payouts.
  • Unable to verify if Achieve Life Sciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Achieve Life Sciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Achieve Life Sciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Achieve Life Sciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Achieve Life Sciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Achieve Life Sciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SP4N Management

 What is the CEO of Achieve Life Sciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rick Stewart
COMPENSATION $1,090,265
AGE 59
TENURE AS CEO 1.7 years
CEO Bio

Dr. Richard A. B. Stewart, also known as Rick, has been Chairman, Chief Executive Officer and Director of Achieve Life Sciences, Inc. since August 2017. Dr. Stewart has been a Founder of Ricanto Limited, a pharmaceutical asset optimization company, since 2009. Dr. Stewart has been Chairman and Chief Executive Officer of Renown Pharma Limited since 2016. Dr. Stewart serves as Financial Strategic & Operational Advisor for Avicena Group Inc. He served as Chief Executive Officer of OncoGenex Pharmaceuticals, Inc. He served as Chairman and Chief Executive Officer of Huxley Pharmaceuticals, Inc. since 2009. Dr. Stewart served as Chief Executive Officer of Brabant Pharma Limited from 2013 to 2014. Dr. Stewart served as Chief Executive Officer of Amarin Corporation plc from November 23, 1998 to December 19, 2007 and was its Founder. Dr. Stewart joined Amarin Corp. PLC in November 1998 and served as its President and Chief Operating Officer. He served as Executive Director of Amarin Corporation plc since November 23, 1998. He was responsible for corporate strategy as Corporate Development Director of SkyePharma PLC and served as its Finance Director. Dr. Stewart was a Co-Founder of SkyePharma plc and served as its Chief Financial Officer and Chief Business Officer from 1995 to 1998. He served as the Chairman of OncoGenex Pharmaceuticals, Inc. since August 1, 2017. He has been a Director of Ricanto Limited, a pharmaceutical asset optimization company, since 2009. He serves as Director of Avicena Group Inc. He served as Director of SkyePharma plc. Dr. Stewart holds a B.S. in Business Administration from the University of Bath, School of Management.

CEO Compensation
  • Rick's compensation has increased whilst company is loss making.
  • Rick's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Achieve Life Sciences management team in years:

2.3
Average Tenure
59.5
Average Age
  • The tenure for the Achieve Life Sciences management team is about average.
Management Team

Rick Stewart

TITLE
Chairman of the Board & CEO
COMPENSATION
$1M
AGE
59
TENURE
1.7 yrs

Tony Clarke

TITLE
President
COMPENSATION
$722K
AGE
62
TENURE
1.7 yrs

John Bencich

TITLE
Executive VP
COMPENSATION
$695K
AGE
41
TENURE
4.7 yrs

Cindy Jacobs

TITLE
Executive VP & Chief Medical Officer
COMPENSATION
$712K
AGE
60
TENURE
10.7 yrs

Jaime Xinos

TITLE
Executive Vice President of Commercial
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the Achieve Life Sciences board of directors in years:

5.3
Average Tenure
62
Average Age
  • The tenure for the Achieve Life Sciences board of directors is about average.
Board of Directors

Rick Stewart

TITLE
Chairman of the Board & CEO
COMPENSATION
$1M
AGE
59
TENURE
1.7 yrs

Tony Clarke

TITLE
President
COMPENSATION
$722K
AGE
62
TENURE
1.7 yrs

Martin Mattingly

TITLE
Non-Employee Director
COMPENSATION
$83K
AGE
61
TENURE
8.8 yrs

H. Parker

TITLE
Non-Employee Director
COMPENSATION
$82K
AGE
62
TENURE
9.1 yrs

Jay Moyes

TITLE
Non-Employee Director
COMPENSATION
$81K
AGE
64
TENURE
1.7 yrs

Don Joseph

TITLE
Lead Independent Director
COMPENSATION
$98K
AGE
64

Scott Cormack

TITLE
Non-Employee Director
COMPENSATION
$62K
AGE
53
TENURE
10.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Achieve Life Sciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Achieve Life Sciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SP4N News

Simply Wall St News

SP4N Company Info

Description

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has a license agreement with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Details
Name: Achieve Life Sciences, Inc.
SP4N
Exchange: DB
Founded:
$24,291,895
6,721,200
Website: http://www.achievelifesciences.com
Address: Achieve Life Sciences, Inc.
1001 West Broadway,
Suite 400,
Vancouver,
British Columbia, V6H 4B1,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM ACHV Common Stock Nasdaq Capital Market US USD 02. Aug 2017
DB SP4N Common Stock Deutsche Boerse AG DE EUR 02. Aug 2017
Number of employees
Current staff
Staff numbers
13
Achieve Life Sciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 22:23
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/02
Last earnings filing: 2019/03/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.